LMNX Luminex Corporation

Luminex Corporation (Nasdaq: LMNX), the worldwide leader in multiplexed solutions, today unveiled the keynote speakers for its sixth annual Planet xMAP USA 2009 multiplexing symposium. Planet xMAP USA 2009 will feature keynote addresses from Dr. Mark McClellan, Dr. Francis Collins, and Dr. Andrea Ferreira-Gonzalez. The Luminex hosted symposium will be held May 4-6, 2009, at the Hyatt Regency Hotel in Austin, Texas.

�We are delighted to have Drs. McClellan, Collins and Ferreira-Gonzalez as our keynote speakers at Planet xMAP USA 2009,� said Patrick J. Balthrop, president and chief executive officer of Luminex Corporation. �The unique insight they will offer on the future of health care, genomics, personalized medicine, and molecular diagnostics will provide a valuable perspective to the symposium.�

Mark B. McClellan, M.P.A., M.D., Ph.D. will be the featured keynote speaker on Monday, May 4, with a presentation titled, �The Future of Health Care: Leading Change to Deliver Value.� Dr. McClellan is the Director of the Engelberg Center for Healthcare Reform and Leonard D. Schaeffer Chair in Health Policy Studies at the Brookings Institution. He has a highly distinguished record in public service and in academic research. He is the former administrator for the Centers for Medicare and Medicaid Services (2004-2006) and the former commissioner of the Food and Drug Administration (2002-2004). Dr. McClellan also served as a member of the President�s Council of Economic Advisers and senior director for health care policy at the White House (2001�2002). In these positions, he developed and implemented major reforms in health policy including the Medicare prescription drug benefit and the FDA�s Critical Path initiative.

Francis S. Collins, M.D., Ph.D., will be the featured keynote speaker on Tuesday, May�5, with a presentation titled, �The Future of Genomics and Personalized Medicine.� Dr.�Collins is a physician-geneticist and former Director of the National Human Genome Research Institute at the National Institutes of Health in Bethesda, Maryland. In this capacity, he oversaw the International Human Genome Sequencing Consortium, and its landmark effort to sequence the entire human DNA code ? the Human Genome Project. Building on the foundation laid by the Human Genome Project, Dr. Collins led the NHGRI effort to ensure that this new trove of sequence data is translated into powerful tools and thoughtful strategies to advance biological knowledge and improve human health. Dr. Collins is also the author of The Language of God which has appeared on The New York Times� Best Seller List.

Andrea Ferreira-Gonzalez, Ph.D., will be the featured keynote speaker on Wednesday, May�6, with a presentation titled, �Navigating the Future of Diagnostic Multiplexing.� Dr.�Ferreira-Gonzalez is a Professor of Pathology at Virginia Commonwealth University and director of the Molecular Diagnostics Laboratory at Virginia Commonwealth University�s Health System. The past-President for the Association for Molecular Pathology, she has been recognized both nationally and internationally for her work in the field of molecular diagnostics. Dr. Ferreira-Gonzalez is a member of the U.S. Department of Health and Human Services� (HHS) Secretary�s Advisory Committee on Genetics, Health and Society (SACGHS) and the Chair of the SACGHS Task Force on Genetic Testing Oversight.

Planet xMAP USA 2009 is a gathering of scientists and researchers from around the world who are performing groundbreaking work in clinical diagnostics and life science research using Luminex�s xMAP� multiplexing technology platform. In addition to these keynote addresses, the symposium will feature a range of dynamic end-user presentations, workshops, discussion groups, scientific posters and networking events.

For additional information regarding the Planet xMAP USA 2009 symposium or to register online, please visit http://www.luminexcorp.com/planetxmap, call 512-219-8020 or e-mail Dawn Fredericy at dawn@luminexcorp.com.

About Luminex Corporation

Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries. The Company�s xMAP� multiplex solutions include an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics markets. The Company�s xMAP Technology is sold worldwide and is already in use in leading clinical laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or xMAP Technology can be obtained at www.luminexcorp.com.

Photos/Multimedia�Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5910126&lang=en

Luminex (NASDAQ:LMNX)
Historical Stock Chart
From Jun 2024 to Jul 2024

Luminex (NASDAQ:LMNX)
Historical Stock Chart
From Jul 2023 to Jul 2024